Koretz and colleagues correctly highlight the need for robust evidence for hepatitis C screening, but a few points warrant a more balanced discussion.
1
The impact of hepatitis C should not be underestimated. Deaths associated with hepatitis C trebled in the UK between 1996 and 2010. By 2020, an estimated 15 480 infected people in the UK will have associated cirrhosis or hepatocellular carcinoma.
2
The US birth cohort screening programme the authors described has shown cost effectiveness.
3 Newer regimens will ultimately improve pricing competition and sustained virological response (SVR) rates compared with interferon based treatments. The authors question the benefit of achieving SVR, despite a meta-analysis of 34 563 treated patients showing a 62% reduction in all cause mortality. 4 The article focuses on whether risks of treatment outweigh benefits. Previous reports suggest achieving SVR is associated with improved quality of life.
5 Traditional interferon based treatments have serious side effects. However, newer direct acting antiviral regimens have greater tolerability. One study that the authors cited used a sofosbuvir and ledipasvir regimen.
1
Of 647 treated patients only three (0.5%) discontinued treatment early because of side effects. Ten (1.5%) experienced serious adverse events. However, it is unclear how many of these events were genuinely attributable to these drugs.
Patients successfully treated with mild to moderate disease may be alarmed to read the authors' interpretation of SVR. These patients should be reassured that ongoing hepatitis C mediated liver damage is unlikely. Reactivation after SVR is exceedingly rare. Conversely, patients with cirrhosis are at risk of disease progression after SVR. This emphasises the importance of early diagnosis and treatment, which is the ultimate goal of screening.
